Pharmaceutical Management Agency
Management in Wellington
www.pharmac.govt.nz
Remember you found this company at Infodats
(04) 460499?
Address
40 Mercer Street. Wellington Central.. 1025, Wellington, Wellington.Are you the owner or manager of this company?
What you should know about Pharmaceutical Management Agency
A response was needed, and in 1993 the Pharmaceutical Management Agency PHARMAC was created to actively manage Government spending on medicines. The move towards assuming management of all medicines used in hospitals, and medical devices, are long term projects that will involve working with District Health Boards, senior clinicians, and medical and patient interest groups in coming years. This means that we can now subsidise about three times the amount of medicines that could be bought with the same money in 1993. PHARMAC is the New Zealand government agency that decides which pharmaceuticals to publicly fund in New Zealand.
PHARMAC's Board, which is appointed by the Minister of Health, is ultimately responsible for all of PHARMAC's decisions. Performance for completed financial years is outlined in the Annual Reports for those years. PHARMAC has also published a short video where you can have a look at how PHARMAC's work in funding medicines has impacted New Zealanders over the last 10 years. PHARMAC must carry out its functions within the amount of funding provided, in accordance with its Statement of Intent and any directions given under the Crown Entities Act external link 10 . a Pharmacology and Therapeutics Advisory Committee PTAC to provide objective advice to PHARMAC in relation to pharmaceuticals and. We refer to our decisions about whether and how particular pharmaceuticals are publicly funded, as funding decisions . PHARMAC maintains and manages the Pharmaceutical Schedule Schedule which reflects PHARMAC’s funding decisions and with which DHBs must comply 15 . The Schedule lists the pharmaceuticals publicly funded in New Zealand, including all medicines which may be given in DHB hospitals, and the pharmaceuticals, including medical devices, used in DHB hospitals and for which PHARMAC has negotiated national prices.
Most Special Authority applications external link are processed by the Ministry of Health. PHARMAC uses the Factors for Consideration to determine whether a proposal or decision helps PHARMAC to achieve its statutory objective of securing for eligible people in need of pharmaceuticals the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided 17 . The Factors for Consideration are taken into consideration to inform funding decisions including funding of pharmaceuticals in exceptional circumstances. 1 The person receiving the medicine or medical device must be an eligible person, as set out in Health and Disability Services Eligibility Direction 2011 under Section 32 of the New Zealand Public Health and Disability Act 200 external link . Cross deal and bundling arrangements involve a decision requiring amendments to the Schedule in respect of more than one pharmaceutical whether or not those pharmaceuticals are in related therapeutic sub groups
During the 1980s medicines prices were increasing at a faster rate than other healthcare spending, and were one of the fastest growing items of Government expenditure. Growth of more than 20 in some years meant medicine prices were threatening to crowd out other healthcare funding.
A response was needed, and in 1993 the Pharmaceutical Management Agency PHARMAC was created to actively manage Government spending on medicines. PHARMAC's role was, in effect, to get better value for medicines so that the best health outcomes could be achieved from public money spent on medicines. PHARMAC's first task was to organise the range of subsidised medicines the Drug Tariff into a cohesive list the Pharmaceutical Schedule. Considerable input from expert clinicians on PTAC the Pharmacology and Therapeutics Advisory Committee was needed to sort medicines into therapeutic groups.
Reviews were then undertaken, so that more informed judgements could be made about decisions affecting each therapeutic group. The introduction of these products, like new treatments for heartburn, raised cholesterol or depression, created significant challenges for medicines funding bodies worldwide and PHARMAC was no exception. From PHARMAC’s creation, there was potential for price reductions through the introduction of price competition between pharmaceutical companies. Tendering for off patent medicines generics was a logical extension of strategies to promote competition.
All of these mechanisms help reduce the amount we pay for medicines, generating savings that are able to be used to subsidise more products increasing New Zealanders’ access to medicines. As well as subsidising medicines, PHARMAC has a strong interest in ensuring they are used well. We also have a M ori Responsiveness Strategy and Pacific Responsiveness Strategy which seek to address inequalities in medicines access, amongst other goals. This means that we can now subsidise about three times the amount of medicines that could be bought with the same money in 1993
PHARMAC's Board, which is appointed by the Minister of Health, is ultimately responsible for all of PHARMAC's decisions. Performance for completed financial years is outlined in the Annual Reports for those years. PHARMAC has also published a short video where you can have a look at how PHARMAC's work in funding medicines has impacted New Zealanders over the last 10 years. PHARMAC must carry out its functions within the amount of funding provided, in accordance with its Statement of Intent and any directions given under the Crown Entities Act external link 10 . a Pharmacology and Therapeutics Advisory Committee PTAC to provide objective advice to PHARMAC in relation to pharmaceuticals and. We refer to our decisions about whether and how particular pharmaceuticals are publicly funded, as funding decisions . PHARMAC maintains and manages the Pharmaceutical Schedule Schedule which reflects PHARMAC’s funding decisions and with which DHBs must comply 15 . The Schedule lists the pharmaceuticals publicly funded in New Zealand, including all medicines which may be given in DHB hospitals, and the pharmaceuticals, including medical devices, used in DHB hospitals and for which PHARMAC has negotiated national prices.
Most Special Authority applications external link are processed by the Ministry of Health. PHARMAC uses the Factors for Consideration to determine whether a proposal or decision helps PHARMAC to achieve its statutory objective of securing for eligible people in need of pharmaceuticals the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided 17 . The Factors for Consideration are taken into consideration to inform funding decisions including funding of pharmaceuticals in exceptional circumstances. 1 The person receiving the medicine or medical device must be an eligible person, as set out in Health and Disability Services Eligibility Direction 2011 under Section 32 of the New Zealand Public Health and Disability Act 200 external link . Cross deal and bundling arrangements involve a decision requiring amendments to the Schedule in respect of more than one pharmaceutical whether or not those pharmaceuticals are in related therapeutic sub groups
During the 1980s medicines prices were increasing at a faster rate than other healthcare spending, and were one of the fastest growing items of Government expenditure. Growth of more than 20 in some years meant medicine prices were threatening to crowd out other healthcare funding.
A response was needed, and in 1993 the Pharmaceutical Management Agency PHARMAC was created to actively manage Government spending on medicines. PHARMAC's role was, in effect, to get better value for medicines so that the best health outcomes could be achieved from public money spent on medicines. PHARMAC's first task was to organise the range of subsidised medicines the Drug Tariff into a cohesive list the Pharmaceutical Schedule. Considerable input from expert clinicians on PTAC the Pharmacology and Therapeutics Advisory Committee was needed to sort medicines into therapeutic groups.
Reviews were then undertaken, so that more informed judgements could be made about decisions affecting each therapeutic group. The introduction of these products, like new treatments for heartburn, raised cholesterol or depression, created significant challenges for medicines funding bodies worldwide and PHARMAC was no exception. From PHARMAC’s creation, there was potential for price reductions through the introduction of price competition between pharmaceutical companies. Tendering for off patent medicines generics was a logical extension of strategies to promote competition.
All of these mechanisms help reduce the amount we pay for medicines, generating savings that are able to be used to subsidise more products increasing New Zealanders’ access to medicines. As well as subsidising medicines, PHARMAC has a strong interest in ensuring they are used well. We also have a M ori Responsiveness Strategy and Pacific Responsiveness Strategy which seek to address inequalities in medicines access, amongst other goals. This means that we can now subsidise about three times the amount of medicines that could be bought with the same money in 1993
Social media
Other users also viewed:
Photos and videos
This business has no pictures or videos
Reviews of Pharmaceutical Management Agency (0)